LVGN3616 + LVGN6051 + LVGN7409 + bevacizumab + cyclophosphamide

This is an investigational combination therapy comprising three novel monoclonal antibodies (LVGN3616, LVGN6051, and LVGN7409), the anti-angiogenic agent bevacizumab (marketed as Avastin), and the alkylating agent cyclophosphamide. The regimen is being studied in a phase 1 clinical trial for metastatic solid tumors including gastric cancer, liver cancer, sarcoma, and HPV-associated cancers. - **LVGN3616** is a PD-1 inhibitor monoclonal antibody designed to enhance immune-mediated tumor cell killing[5]. - **LVGN6051** and **LVGN7409** are also investigational monoclonal antibodies with immunomodulatory properties; available data suggest they may target other immune checkpoints or costimulatory molecules[3][5]. - **Bevacizumab** is an approved anti-VEGF-A monoclonal antibody that inhibits angiogenesis. - **Cyclophosphamide** is a well-established small molecule alkylating chemotherapeutic that suppresses rapidly dividing cells including tumor cells. The combination aims to leverage both direct cytotoxic effects (cyclophosphamide), inhibition of tumor blood vessel formation (bevacizumab), and enhanced antitumor immunity via checkpoint blockade or immune modulation (the three investigational antibodies). The developer of the investigational agents is Lvygen Biopharma; MD Anderson Cancer Center holds the IND for this trial[3][5].